Figure 1: OT-82 potently decreases the viability of leukemia cell lines and pediatric ALL PDX cells.

(A) Cytotoxicity of OT-82 against a panel of leukemia cell lines (n=14) as evaluated by resazurin reduction assays 72h after compound administration. Each data point represents the mean % viability (relative to vehicle-treated cells) ± SEM of at least 3 independent experiments. IC₅₀ values were estimated by non-linear regression of transformed data. (B) Number of live RS4;11 and PER-485 cells after treatment with 1 nM OT-82 or vehicle compared to the number of living cells on the day of seeding as determined by trypan blue exclusion assay. Each data point represents the mean ± SEM of at least 3 independent experiments. Mean % of live cells after OT-82 and vehicle treatment for each time point were compared by paired t-test. (C) Cytotoxicity of OT-82 against a panel of PDX cells derived from pediatric patients with high-risk or poor outcome ALL as evaluated by resazurin reduction assays 72h after compound administration. Each data point represents the mean % viability (relative to vehicle-treated cells) ± SEM of at least 2 independent experiments, except for PAKRSL (n=1). IC₅₀ values were estimated by point-by-point regression of transformed data. **, P<0.01; ****, P<0.0001.